A clinical trial investigating the use of a drug called metformin as a way of reducing the cancer risk in people with Li Fraumeni Syndrome (LFS)

This trial is open to people aged 16 and older who have a confirmed genetic diagnosis of Li Fraumeni Syndrome (a known alteration in their TP53 gene). You must be able to attend yearly hospital check-ups and give blood samples.

You cannot join the study if you currently have active cancer or are receiving cancer treatment, although some long-term hormone therapies are permitted. You are also not eligible if you have diabetes, are currently taking metformin, or have taken metformin for more than three months in the past two years.

Because the body processes metformin through the kidneys and liver, people with significant kidney, liver, or heart problems cannot take part. The trial is also not suitable for anyone who is pregnant, breastfeeding, or unable to have an MRI scan due to certain metal implants or pacemakers.

Taking part in the study lasts for up to five years. A computer randomly places you into one of two groups: one group takes metformin tablets once a day, and the other group has regular check-ups without the medication. Both groups receive the same high standard of care. Once a year, you will visit a specialist trial hospital for a thorough health check, blood tests, and a whole-body MRI scan to look for any early changes in your body. Every six months, a research nurse will phone you to check on your health and discuss any symptoms. You will also be asked to answer occasional questionnaires about your wellbeing.